{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': 'An der Goldgrube 12',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 84,
 'askSize': 1000,
 'averageDailyVolume10Day': 7806312,
 'averageVolume': 2660160,
 'averageVolume10days': 7806312,
 'beta': None,
 'beta3Year': None,
 'bid': 83.7,
 'bidSize': 1400,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Mainz',
 'companyOfficers': [],
 'country': 'Germany',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 86.7,
 'dayLow': 80.34,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 19088050176,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '49 6131 9084 390',
 'fiftyDayAverage': 65.33629,
 'fiftyTwoWeekHigh': 105,
 'fiftyTwoWeekLow': 12.525,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 66455536,
 'forwardEps': -0.89,
 'forwardPE': -94.57304,
 'fromCurrency': None,
 'fullTimeEmployees': 1400,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.012569999,
 'heldPercentInstitutions': 0.04147,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/biontech.de',
 'longBusinessSummary': 'BioNTech SE, a biotechnology company, develops and '
                        'commercializes immunotherapies for cancer and other '
                        'infectious diseases. The company is involved in '
                        'developing FixVac product candidates, including '
                        'BNT111, which is in Phase I clinical trial for '
                        'advance melanoma; BNT112 that is in Phase I/II trial '
                        'for prostate cancer; BNT113, which is in Phase I '
                        'trial to treat HPV+ head and neck cancers; BNT114 '
                        'that is in Phase I clinical trial for triple negative '
                        'breast cancer; BNT115 in a Phase I trial in ovarian '
                        'cancer; and BNT116, which is in preclinical trail for '
                        'non-small cell lung cancer. It also develops '
                        'individualized neo-antigen specific immunotherapies, '
                        'such as RO7198457, which is in Phase II clinical '
                        'trial for first-line melanoma, as well as in Phase I '
                        'clinical trial to treat multiple solid tumors; mRNA '
                        'intratumoral immunotherapy comprising SAR441000 that '
                        'is in Phase I clinical trial for solid tumors; and '
                        'BNT141 and BNT142 to treat multiple solid tumors. In '
                        'addition, the company develops RiboCytokines, which '
                        'include BNT151, BNT152, and BNT152 for multiple solid '
                        'tumors; chimeric antigen receptor T cell '
                        'immunotherapies, such as BNT211 to treat multiple '
                        'solid tumors, and BNT212 for pancreatic and other '
                        'cancers; and next-generation checkpoint '
                        'immunomodulators consisting of GEN1046 and GEN1042, '
                        'which are in Phase I/II a clinical trial to treat '
                        'multiple solid tumors. Further, it develops MVT-5873, '
                        'an IgG1 monoclonal antibody, which is in Phase I/II '
                        'clinical trial for pancreatic cancer; BNT411, small '
                        'molecule immunomodulator product candidate for solid '
                        'tumors; and infectious disease immunotherapies and '
                        'rare disease protein replacement therapies. The '
                        'company has collaborations with Genentech, Inc., '
                        'Sanofi S.A., Genmab A/S, Genevant Sciences GmbH, Eli '
                        'Lilly and Company, Bayer AG, Pfizer Inc., and '
                        'Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The '
                        'company was founded in 2008 and is headquartered in '
                        'Mainz, Germany.',
 'longName': 'BioNTech SE',
 'market': 'us_market',
 'marketCap': 19584086016,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_51198843',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 86.3,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 3.6,
 'phone': '49 6131 9084 0',
 'previousClose': 88.51,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -1.74205,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 86.7,
 'regularMarketDayLow': 80.34,
 'regularMarketOpen': 86.3,
 'regularMarketPreviousClose': 88.51,
 'regularMarketPrice': 86.3,
 'regularMarketVolume': 7109730,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 232672992,
 'sharesPercentSharesOut': 0.0145000005,
 'sharesShort': 3279761,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2332882,
 'shortName': 'BioNTech SE',
 'shortPercentOfFloat': None,
 'shortRatio': 2.29,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'BNTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 48.626114,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ec5204aa-33b4-3ae1-bc3a-4bb94e6f559d',
 'volume': 7109730,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.biontech.de',
 'yield': None,
 'ytdReturn': None,
 'zip': '55131'}